lesions was increased by more than 10% on T1-weighted MRI. Most of the patients in the MRI group were also examined by magnetic resonance spectroscopy to help distinguish recurrence from radiation injury. The patients in the PET group were judged to have recurrent lesions when the MET uptake exceeded the previously reported threshold (lesion and control ratio of more than 1.4).[15,16] The former received radiation only in areas with enhancement. The latter received radiation only in areas with elevated MET uptake, regardless of the lesions enhanced on MRI. Over the first years of the study period, the PET-MR fusion images were produced with Dr. View (Infocom Co, Ltd, Tokyo, Japan), a medical image analysis program for personal computers (n = 25). The fusion images were transferred into the Leksell Gamma Plan System (Elekta, AB, Stockholm). From 2009 onward, when Gamma Plan version 8.0 became available, the image fusion was conducted using an automated program capable of fusing MET-PET and MRI data (n = 9). The re-SRS was performed within 2 weeks or less from diagnosis in most of the patients in the 2 groups and within 6 weeks from diagnosis at the longest. Representative planning of PET-based GK treatment was demonstrated in Figure 1.

Statistical Analysis

The data were analyzed statistically using JMP (Japanese version 10.0, SAS Institute Inc, Cary, NC) running on personal computers. The overall survival period was defined as the interval between the day of GK treatment and either the last day of follow-up or the day of death by any cause. An analysis of time-to-event outcomes was performed using the Kaplan-Meier method with the log-rank test or regression analysis with the proportional hazard model. The odds ratios (OR) and 95% confidence intervals (CI) were estimated using the Cox proportional hazards model. Comparisons between groups were performed using the Wilcoxon rank sum test and the Fisher exact tests. $P < 0.05$ was considered to indicate statistically significant differences.

RESULTS

Table 1 shows the results of a statistical comparison of various clinical parameters between the 2 groups of patients treated using different modalities for planning, one with PET-MRI fusion imaging (PET group) and the other with MRI imaging (MRI group). The factors compared were sex, age, type and status of the primary lesion, KPS, recursive partitioning analysis class,[17] metastases to extracranial lesion, number of brain lesions, and dose and volume in GK radiation planning. The MRI and PET groups differed significantly in sex, age, and the ratio of breast cancer. The total irradiation volume was significantly smaller in the PET group than in the MRI group (6.87 vs 10.9 cc; $P = 0.0497$), and the minimal irradiation dose in the PET group was significantly higher (21 vs 19 Gy; $P = 0.04$). No statistically significant differences were found between the 2 groups in the other factors compared.

Figure 2 shows a statistical comparison between the 2 groups in overall survival. Follow-up visits in person and follow-up inquiries by telephone confirmed that 8 patients in the PET group and 2 patients in the MR group survived throughout the whole study period. The median survival time after the final GK was significantly longer in the PET group than in the MRI group (18.1 vs 8.6 months; $P = 0.01$). Table 2 shows the results of a multivariable analysis with a Cox proportional hazards model to examine if the use of PET-MRI fusion images independently contributed to a longer patient survival. The use of MET-PET (OR = 0.54; CI, 0.33–0.90; $P = 0.02$) was independently associated with a prolonged posttreatment survival time, the KPS (by 10% increase, OR, 0.71; CI, 0.57–0.88; $P = 0.002$), the


FIGURE 1. Representative plan for GK surgery for locally recurring brain metastases with guidance from MET-PET/MRI fusion imaging. The patient was a 42-year-old woman with brain metastases from breast cancer who had received 4 previous treatments with GK. A big discrepancy was clearly seen between the area with Gd contrast enhancement on the T1-weighted MR image (**A,** indicated by arrowheads) and the area with elevated MET uptake (**B,** indicated by arrows). **C,** The PET-MRI fusion image was rendered after constructing a binary image (shown in white) indicating areas with MET uptake 1.4 times higher than that in the contralateral brain.[15,16] **D,** The GK strategy was to administer a higher radiation dose to areas with higher MET uptake. [11]C methionine uptake was markedly reduced in a MET-PET image obtained 6 months after the GK (ie, good control of active cancer).

299

TABLE 1. Preradiosurgical Clinical Factors Between Patients Treated Only With Enhanced MRI (MRI Group) and With ^{11}C Methionine PET (PET Group)

	PET Group (n = 34)	MRI Group (n = 54)	P
Sex, n			0.005
Male	12	36	
Female	22	18	
Age, mean (range), y	58 (37–80)	63 (38–80)	0.03
Origin			0.07
Lung	18	34	
Breast	12	7	
Gastrointestinal	0	9	
Others	4	4	
Ratio of breast cancer	12/34 (35.3%)	7/54 (13.0%)	0.02
RPA class			0.36
Class 1	8	11	
Class 2	26	40	
Class 3	0	3	
KPS, median (range), %	90 (70–100)	90 (60–100)	0.41
State of original cancer			0.18
Good control	23	28	
Poor control	11	26	
Extracerebral metastases, n	13	16	0.49
No. lesions, median (range)	2 (1–35)	1 (1–25)	0.44
Radiosurgical characteristics			
Total tumor volume, mean (range), cc	6.87 (0.28–38.5)	10.9 (0.03–41.1)	0.0497
Maximum dose, mean (range), Gy	32 (20–48)	32 (20–50)	0.78
Minimum Dose, mean (range), Gy	21 (12–25)	19 (12–25)	0.04

Wilcoxon rank sum test or Fisher exact test was used for comparison.
RPA, Recursive partitioning analysis.

FIGURE 2. Graph depicting survival curves plotted by the Kaplan-Meier method for 2 groups of patients treated using different modalities for planning, one with PET-MRI fusion imaging (PET group, solid line) and the other with MRI imaging (MRI group, dotted line). The length of survival after GK treatment significantly differed between the 2 groups (P = 0.01, log-rank test). The difference in the median survival time between the 2 groups was close to 10 months (18.1 months in PET vs 8.6 months in MRI). Follow-up visits in person and follow-up inquiries by telephone confirmed that 8 patients in the PET group and 2 patients in the MR group survived throughout the whole study period.

number of lesions (OR, 1.06; CI, 1.007–1.11; P = 0.03), and sex (male to female, OR, 2.08; CI, 1.13–4.01; P = 0.02).

Improvements in various treatments against cancer over time may have contributed to the better survival of the PET group, as many of the PET patients were treated more recently (2005–2011) than the MRI group patients (1998–2011) overall. Yet according to an analysis of the post-GK survival time in the MRI group patients treated from 2005 to 2011 (n = 28), the median survival (7.8 months) was shorter than that of the patients in all MRI group patients (8.7 months) and significantly shorter than that of the PET group overall (P = 0.01).

TABLE 2. Preradiosurgical Clinical Factors Affecting Post–Re-Treatment Survival Period in Patients With Local Recurrence

	Odds Ratio	(95% CI)	P
Sex (Male to Female)	2.08	(1.13–4.01)	0.02
Age (continuous)	1.003	(0.98–1.03)	0.82
Origin (breast to others)	1.16	(0.48–2.81)	0.74
RPA class	1.56	(0.29–8.08)	0.60
KPS (by increase of 10%)	0.71	(0.57–0.88)	0.002
State of original cancer (good to poor)	0.75	(0.40–1.39)	0.37
Extracerebral metastases (yes to no)	1.54	(0.75–3.05)	0.23
Number of lesions (continuous)	1.06	(1.007–1.11)	0.03
Using MET-PET (yes to no)	0.54	(0.33–0.90)	0.02

Regression analysis with the proportional hazard model.

From this result, we concluded that the difference in the treatment period had little influence on the patients' survival.

DISCUSSION

The present report is the first to show the clinical benefit of PET-MRI fusion images for the planning of the GK-SRS intervention against metastatic brain tumors. Using MET as a suitable probe for PET brain tumor imaging, we statistically demonstrated that patients undergoing GK-SRS survived significantly longer after procedures performed using PET-MRI guidance versus those performed using MRI information alone.

Metastasis is a life-threatening process estimated to occur in 10% to 30% of all cancer patients.[18] The management of brain metastases is hence crucial for patients' prognosis. Whole-brain radiotherapy (WBRT) is being superseded by SRS without WBRT as a treatment of choice for brain metastases, even for patients with 5 or more lesions.[19] Whereas no clear consensus has been reached on the best approach to metastases,[20] WBRT poses grave problems: patients who achieve long-term survival may have decreased cognitive function or may be prohibited from receiving a second WBRT interventions even when metastases recur. Patients managed with SRS usually fare much better cognitively,[21] and any adverse events associated with the intervention tend to be manageable.[22] Patients may thus receive a second SRS safely and effectively when lesions recur.

Particular concern, however, is merited for patients who receive a second GK-SRS on the occurrence of radiation-induced necrosis. Conventional morphological MRI may be poor in differentiating tumor recurrence from radiation necrosis, as necrotic lesions without viable tumors are often well enhanced by Gd and occasionally grow in much the same way as recurrent tumors.[23] Magnetic resonance techniques such as the detection of T1 and T2 mismatch,[24] magnetic resonance spectroscopy,[25,26] and perfusion-weighted MRI[27–30] have been proposed as useful means for differentiating tumor recurrence from radiation necrosis. These maneuvers have high sensitivity and specificity for differentiation and thus may be sufficient for differentiation when an enhanced lesion is pure tumor or pure necrosis. Such instances may be rare, however, as tumors detected in formerly irradiated regions usually turn out to be a mixture of active tumor and necrotic tissue (Fig. 1). The MRI method may not work well in prospectively picking up active tumor tissue out of mixed tumors of this type.[31] Hence, PET metabolic imaging has considerable advantages over MRI as a source of guidance for GK treatment.

Among the various PET methods, ^{18}F-FDG has been considered useful for whole-body cancer imaging. Now, however, FDG is widely believed to be unsuitable for brain tumors. The physiological use of glucose in normal brain is generally higher than that of most metastatic tumors,[32] and high uptake of FDG into inflammatory tissues[33] may also hamper the detection of active tumors.

In contrast to glucose, amino acid uptake is lower in the brain than in most tumors. Amino acid imaging thus holds promise for the detection and focal treatment of malignant tumors of the brain. Our group previously reported the advantages of MET-PET imaging for the surgical resection of glial tumors.[13,14] When used for glioma surgery, MRI and MET-PET detect different tumor margins. [11]C methionine PET reportedly detect tumors invading far beyond the area with Gd enhancement,[34] and patients with remnant malignant gliomas in areas without Gd enhancement generally have worse outcome than patients without remnant tumor detectable by MET-PET.[12] Hence, the resection area determined with MET-PET is usually larger than that detected by enhanced MRI.

When GK-SRS is performed for focally recurrent brain metastases, the active tumor area detected with PET is smaller than that detected with Gd enhancement on MRI (Fig. 1). The same difference was manifested as a smaller total irradiation volume in the PET group

versus the MRI group (Table 1). We suspect that the smaller irradiation volume in the PET group may have led to a significantly higher marginal dose in the PET group than in the MRI group (Table 1). We believe that the current results are quite reasonable, as a prior study has already demonstrated that a lower marginal dose leads to higher rate of local recurrence.[35]

The retrospective noncontrolled protocol of this study, however, made it difficult to wholly eliminate selection bias. With regard to sex difference, an analysis of the influence of breast and gynecologic cancers known to have a better prognosis than other cancers[36,37] indicated that the different rates of malignancy were not independently associated with prolonged overall survival. Next, with regard to a potential lead time bias (ie, improved survival in the PET group versus the MR group attributable to the earlier diagnosis of the former), no significant difference between the 2 groups was found at the time between the re-SRS and previous SRS (54.5 weeks in the PET group vs 37.9 weeks in the MR group; $P = 0.06$).

This retrospective study is the first to show the clinical benefit of PET-MRI fusion imaging as guidance for the GK-SRS intervention. We thus believe the study has value as an initial preliminary report on the use of a new technique. Our analysis, however, was performed under rather specific conditions. Although GK treatment was performed at a single institute and managed by a single specialist (M. Y.) with ample experience with GK treatment for metastatic brain tumors,[19,22,38,39] the patients were referred from multiple institutes. Most of the patients in the PET group were referred from the institute of the chief investigator, whereas all of the patients in the MRI group were referred from other institutes without available PET facilities. Hence, factors other than planning may have influenced the patient outcomes. Further, the number of focally recurrent patients who underwent repeated GK was small relative to the population of patients with brain metastases out of which they were selected (88 of 2502). In view of these limitations, we believe that our data constitute only preliminary evidence that MET-PET/MRI fusion imaging improves the outcome of GK-SRS for metastatic brain tumors. We propose a further prospective analysis with a larger population to confirm the usefulness of PET-based GK-SRS.

CONCLUSION

The results of our retrospective study indicated that MET-PET/MRI fusion images for dose planning prolong the survival of patients undergoing GK-SRS for locally recurring brain metastases compared with similar patients undergoing GK-SRS using MRI alone. A further prospective study on a larger number of patients will be necessary to clarify the real benefit of GK-SRS using MET-PET fusion images.

REFERENCES

1. Fokas E, Henzel M, Engenhart-Cabillic R. A comparison of radiotherapy with radiotherapy plus surgery for brain metastases from urinary bladder cancer: analysis of 62 patients. *Strahlenther Onkol.* 2010;186:565–571.

2. Meisner J, Meyer A, Polivka B, et al. Outcome of moderately dosed radiosurgery for limited brain metastases. Report of a single-center experience. *Strahlenther Onkol.* 2010;186:76–81.

3. Suh JH. Stereotactic radiosurgery for the management of brain metastases. *N Engl J Med.* 2010;362:1119–1127.

4. Chen JC, Petrovich Z, Giannotta SL, et al. Radiosurgical salvage therapy for patients presenting with recurrence of metastatic disease to the brain. *Neurosurgery.* 2000;46:860–866; discussion 866–867.

5. Kwon KY, Kong DS, Lee JI, et al. Outcome of repeated radiosurgery for recurrent metastatic brain tumors. *Clin Neurol Neurosurg.* 2007;109:132–137.

6. Shuto T, Fujino H, Inomori S, et al. Repeated gamma knife radiosurgery for multiple metastatic brain tumours. *Acta Neurochir (Wien).* 2004;146:989–993; discussion 993.

7. Yamanaka K, Iwai Y, Yasui T, et al. Gamma knife radiosurgery for metastatic brain tumor: the usefulness of repeated gamma knife radiosurgery for recurrent cases. *Stereotact Funct Neurosurg.* 1999;72(suppl 1):73–80.

301

8. Huber PE, Hawighorst H, Fuss M, et al. Transient enlargement of contrast uptake on MRI after linear accelerator (linac) stereotactic radiosurgery for brain metastases. *Int J Radiat Oncol Biol Phys*. 2001;49:1339–1349.

9. Peterson AM, Meltzer CC, Evanson EJ, et al. MR imaging response of brain metastases after gamma knife stereotactic radiosurgery. *Radiology*. 1999;211:807–814.

10. Plowman PN. Stereotactic radiosurgery. VIII. The classification of postradiation reactions. *Br J Neurosurg*. 1999;13:256–264.

11. Ruge MI, Kickingereder P, Grau S, et al. Stereotactic biopsy combined with stereotactic (125)iodine brachytherapy for diagnosis and treatment of locally recurrent single brain metastases. *J Neurooncol*. 2011;105:109–118.

12. Nariai T, Tanaka Y, Wakimoto H, et al. Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. *J Neurosurg*. 2005;103:498–507.

13. Nariai T, Senda M, Ishii K, et al. Three-dimensional imaging of cortical structure, function and glioma for tumor resection. *J Nucl Med*. 1997;38:1563–1568.

14. Tanaka Y, Nariai T, Momose T, et al. Glioma surgery using a multimodal navigation system with integrated metabolic images. *J Neurosurg*. 2009;110: 163–172.

15. Terakawa Y, Tsuyuguchi N, Iwai Y, et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. *J Nucl Med*. 2008;49:694–699.

16. Tsuyuguchi N, Sunada I, Iwai Y, et al. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? *J Neurosurg*. 2003;98: 1056–1064.

17. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. *Int J Radiat Oncol Biol Phys*. 1997;37:745–751.

18. Patchell RA. The management of brain metastases. *Cancer Treat Rev*. 2003; 29:533–540.

19. Yamamoto M, Kawabe T, Sato Y, et al. A case-matched study of stereotactic radiosurgery for patients with multiple brain metastases: comparing treatment results for 1–4 vs ≥5 tumors: clinical article. *J Neurosurg*. 2013;118: 1258–1268.

20. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. *JAMA*. 2006;295:2483–2491.

21. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. *Lancet Oncol*. 2009;10:1037–1044.

22. Yamamoto M, Kawabe T, Higuchi Y, et al. Delayed complications in patients surviving at least 3 years after stereotactic radiosurgery for brain metastases. *Int J Radiat Oncol Biol Phys*. 2013;85:53–60.

23. Dooms GC, Hecht S, Brant-Zawadzki M, et al. Brain radiation lesions: MR imaging. *Radiology*. 1986;158:149–155.

24. Kano H, Kondziolka D, Lobato-Polo J, et al. Differentiating radiation effect from tumor progression after stereotactic radiosurgery: T1/T2 matching. *Clin Neurosurg*. 2010;57:160–165.

25. Chernov M, Hayashi M, Izawa M, et al. Differentiation of the radiation-induced necrosis and tumor recurrence after gamma knife radiosurgery for brain metastases: importance of multi-voxel proton MRS. *Minim Invasive Neurosurg*. 2005;48:228–234.

26. Kimura T, Sako K, Tanaka K, et al. Evaluation of the response of metastatic brain tumors to stereotactic radiosurgery by proton magnetic resonance spectroscopy, 201TlCl single-photon emission computerized tomography, and gadolinium-enhanced magnetic resonance imaging. *J Neurosurg*. 2004;100: 835–841.

27. Barajas RF, Chang JS, Sneed PK, et al. Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. *AJNR Am J Neuroradiol*. 2009;30:367–372.

28. Hoefnagels FW, Lagerwaard FJ, Sanchez E, et al. Radiological progression of cerebral metastases after radiosurgery: assessment of perfusion MRI for differentiating between necrosis and recurrence. *J Neurol*. 2009;256:878–887.

29. Mitsuya K, Nakasu Y, Horiguchi S, et al. Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery. *J Neurooncol*. 2010;99:81–88.

30. Truong MT, St Clair EG, Donahue BR, et al. Results of surgical resection for progression of brain metastases previously treated by gamma knife radiosurgery. *Neurosurgery*. 2006;59:86–97; discussion 86–97.

31. Inaji M, Nariai T, Tanaka Y, et al. Validation of T1/T2 mismatch for accurate differentiation between radiation injury and recurrence of metastatic brain tumor after gamma knife surgery—comparison with methionine PET. *J Radiosurg SBRT*. 2013;Abstract 242:142.

32. Lee HY, Chung JK, Jeong JM, et al. Comparison of FDG-PET findings of brain metastasis from non–small-cell lung cancer and small-cell lung cancer. *Ann Nucl Med*. 2008;22:281–286.

33. Belohlavek O, Simonova G, Kantorova I, et al. Brain metastases after stereotactic radiosurgery using the Leksell gamma knife: can FDG PET help to differentiate radionecrosis from tumour progression? *Eur J Nucl Med Mol Imaging*. 2003;30:96–100.

34. Miwa K, Shinoda J, Yano H, et al. Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study. *J Neurol Neurosurg Psychiatry*. 2004;75:1457–1462.

35. Luther N, Kondziolka D, Kano H, et al. Predicting tumor control after resection bed radiosurgery of brain metastases. *Neurosurgery*. 2013;73:1001–1006.

36. Gonda DD, Kim TE, Goetsch SJ, et al. Prognostic factors for stereotactic radiosurgery–treated patients with cerebral metastasis: implications on randomised control trial design and inter-institutional collaboration. *Eur J Cancer*. 2014;50:1148–1158.

37. Nasu K, Satoh T, Nishio S, et al. Clinicopathologic features of brain metastases from gynecologic malignancies: a retrospective study of 139 cases (KCOG-G1001s trial). *Gynecol Oncol*. 2013;128:198–203.

38. Yamamoto M, ed. *Japanese experience with gamma knife radiosurgery*. Basel: Karger; 2009.

39. Yamamoto M, Sato Y, Serizawa T, et al. Subclassification of recursive partitioning analysis Class II patients with brain metastases treated radiosurgically. *Int J Radiat Oncol Biol Phys*. 2012;83:1399–1405.

302

Stereotactic radiosurgery for patients with multiple brain metastases: a case-matched study comparing treatment results for patients with 2–9 versus 10 or more tumors

Clinical article

MASAAKI YAMAMOTO, M.D.,[1,2] TAKUYA KAWABE, M.D.,[1,3] YASUNORI SATO, PH.D.,[4] YOSHINORI HIGUCHI, M.D.,[5] TADASHI NARIAI, M.D., PH.D.,[6] SHINYA WATANABE, M.D.,[1,7] AND HIDETOSHI KASUYA, M.D.[2]

[1]Katsuta Hospital Mito GammaHouse, Hitachi-naka; [2]Department of Neurosurgery, Tokyo Women's Medical University Medical Center East, Tokyo; [3]Department of Neurosurgery, Kyoto Prefectural University of Medicine Graduate School of Medical Sciences, Kyoto; [4]Clinical Research Center, Chiba University Graduate School of Medicine, Chiba; [5]Department of Neurosurgery, Chiba University Graduate School of Medicine, Chiba; [6]Department of Neurosurgery, Graduate School, Tokyo Medical and Dental University School of Medicine, Tokyo; and [7]Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

Object. Although stereotactic radiosurgery (SRS) alone is not a standard treatment for patients with 4–5 tumors or more, a recent trend has been for patients with 5 or more, or even 10 or more, tumors to undergo SRS alone. The aim of this study was to reappraise whether the treatment results for SRS alone for patients with 10 or more tumors differ from those for patients with 2–9 tumors.

Methods. This was an institutional review board–approved, retrospective cohort study that gathered data from the Katsuta Hospital Mito GammaHouse prospectively accumulated database. Data were collected for 2553 patients who consecutively had undergone Gamma Knife SRS alone, without whole-brain radiotherapy (WBRT), for newly diagnosed (mostly) or recurrent (uncommonly) brain metastases during 1998–2011. Of these 2553 patients, 739 (28.9%) with a single tumor were excluded, leaving 1814 with multiple metastases in the study. These 1814 patients were divided into 2 groups: those with 2–9 tumors (Group A, 1254 patients) and those with 10 or more tumors (Group B, 560 patients). Because of considerable bias in pre-SRS clinical factors between groups A and B, a case-matched study, which used the propensity score matching method, was conducted for clinical factors (i.e., age, sex, primary tumor state, extracerebral metastases, Karnofsky Performance Status, neurological symptoms, prior procedures [surgery and WBRT], volume of the largest tumor, and peripheral doses). Ultimately, 720 patients (360 in each group) were selected. The standard Kaplan-Meier method was used to determine post-SRS survival times and post-SRS neurological death–free survival times. Competing risk analysis was applied to estimate cumulative incidence for local recurrence, repeat SRS for new lesions, neurological deterioration, and SRS-induced complications.

Results. Post-SRS median survival times did not differ significantly between the 2 groups (6.8 months for Group A vs 6.0 months for Group B; hazard ratio [HR] 1.133, 95% CI 0.974–1.319, p = 0.10). Furthermore, rates of neurological death were very similar: 10.0% for group A and 9.4% for group B (p = 0.89); neurological death–free survival times did not differ significantly between the 2 groups (HR 1.073, 95% CI 0.649–1.771, p = 0.78). The cumulative incidence of local recurrence (HR 0.425, 95% CI 0.0.181–0.990, p = 0.04) and repeat SRS for new lesions (HR 0.732, 95% CI 0.554–0.870, p = 0.03) were significantly lower for Group B than for Group A patients. No significant differences between the groups were found for cumulative incidence for neurological deterioration (HR 0.994, 95% CI 0.607–1.469, p = 0.80) or SRS-related complications (HR 0.541, 95% CI 0.138–2.112, p = 0.38).

Conclusions. Post-SRS treatment results (i.e., median survival time; neurological death–free survival times; and cumulative incidence for local recurrence, repeat SRS for new lesions, neurological deterioration, and SRS-related complications) were not inferior (neither less effective nor less safe) for patients in Group B than for those in Group A. We conclude that carefully selected patients with 10 or more tumors are not unfavorable candidates for SRS alone. A randomized controlled trial should be conducted to test this hypothesis.
(*http://thejns.org/doi/abs/10.3171/2014.8.GKS141421*)

KEY WORDS • brain metastases • radiation therapy • radiosurgery • Gamma Knife • tumor number • stereotactic radiosurgery

---

SINCE Sturm et al. reported successful treatment of brain metastases with use of stereotactic radiosurgery (SRS),[25] evidence of the effectiveness of this treatment strategy has been accumulating, for both SRS

alone and SRS in combination with whole-brain radio-therapy (WBRT).[1,3,10,13,15,23,24] Among patients with brain metastases, numerous factors affect outcomes, such that a one-size-fits-all treatment paradigm is no longer appropriate. Nevertheless, a solid patient selection criterion is still necessary before SRS treatment of brain metastases. SRS alone for patients with 4 or more, or even 5 or more, metastatic tumors is not a standard treatment, and in most industrialized nations, WBRT is still strongly recommended.[17] However, by the early 21st century, a trend for patients with 5 or more tumors to be potential candidates for SRS alone had already become apparent.[3,8,13,15,16,20,23,24,26–30,32] Very recently, in a prospective observational study of 1194 brain metastasis patients, Yamamoto et al. showed that SRS without WBRT as the initial treatment was not inferior (in terms of overall survival as well as most secondary end points) for patients with 5–10 metastatic brain tumors compared with those with 2–4 metastatic tumors.[35] Considering the present lack of evidence supporting the superiority of WBRT over SRS alone for patients with 5–10 tumors, their results are considered to constitute the highest level of evidence to date, allowing SRS alone to be advocated for such patients. Existing treatment guidelines for managing brain metastasis patients need to be revised in the very near future.

The next step is to reappraise whether SRS alone is inferior for patients with 10 or more metastatic tumors compared to patients with fewer metastatic tumors. Very recently, 2 studies evaluating outcomes in patients with 10 or more metastatic brain tumors treated with SRS were published in the Journal of Neurosurgery.[8,20] Grandhi et al. studied 61 patients with 10 or more metastatic brain tumors (mean 13 tumors) treated with SRS and found median survival time after SRS to be 4 months; they concluded that SRS safely and effectively treats intracranial disease with a high rate of local control in patients with 10 or more metastatic brain tumors.[8] These authors stated that SRS might be one of the most effective treatment options available for patients with fewer tumors, a non-melanomatous primary lesion, controlled systemic disease, and assignment to a low recursive partitioning analysis (RPA) class. Grandhi et al. concluded that SRS can thus be regarded as a first-line treatment. Rava et al. studied 53 patients with 10 or more metastatic brain tumors treated with SRS (mean number of tumors = 11) and found that post-SRS median survival time exceeded 6 months; they concluded that aggressive local treatment remains an option, although rapid CNS failure is to be expected.[20] Patients with breast cancer represent a group of patients likely to benefit greatly from SRS alone; survival time and time to CNS recurrence are extended. Although these 2 articles discuss several important issues and present significant potential treatment advances, a common weakness is that sample sizes were relatively small (61 and 53 patients).[8,20]

Therefore, we conducted this retrospective cohort study, based on our SRS-treated brain metastasis patients, including 560 patients with 10 or more tumors, to reappraise whether treatment results were truly inferior for patients with 10 or more versus 2–9 tumors and to identify factors determining inferiority and/or noninferior-ity. We excluded patients with only 1 tumor because it is widely recognized that survival periods are much longer for patients with a single brain metastastic tumor than for those with multiple metastatic brain tumors.[13,23,24,30]

Methods

Patient Population

This retrospective cohort study used the prospectively accumulated Katsuta Hospital Mito GammaHouse database of 2553 patients who consecutively underwent SRS alone, without WBRT, for newly diagnosed (mostly) or recurrent (uncommonly) brain metastases during the 13-year-period July 1998 through June 2011. The study was approved by the institutional review board of Tokyo Women's Medical University. Because all patients had been referred to the Katsuta Hospital Mito GammaHouse for SRS, their primary physicians had made most of the patient selections. Patient selection criteria may thus have differed among referring physicians. Therefore, one author (M.Y.) decided whether to accept a patient. We did not perform SRS on patients with low Karnofsky Performance Status (KPS) scores[14] resulting from systemic diseases, a noncooperative state resulting from poor neurocognitive function, meningeal dissemination, or an anticipated survival period of 3 months or less. Therefore, only 173 (6.8%) patients were categorized into RPA Class III,[6] while 1189 (46.6%) were categorized into modified-RPA Class IIc+III.[33,34] Also, the primary physicians responsible for each patient decided the indications for both surgery and radiotherapy. Therefore, before undergoing SRS, 468 (18.3%) of the 2553 patients had undergone surgical removal of brain metastases and 125 (4.9%) had undergone WBRT.

Before SRS, the first author (M.Y.) explained the treatment strategy in detail to each patient and at least 1 adult relative of the patient. Written informed consent was obtained from all patients. Because our previous report[32,33] describes our radiosurgical techniques and dose selection for multiple brain metastases in detail, they are not repeated herein. In brief, before June 2003, standard SRS procedures were performed by using a Leksell Gamma Unit Model B and thereafter a Leksell Gamma Unit Model C (Elekta AB). For target coordinate determination and dose planning, until August 2002 stereotactic single-dose gadolinium-enhanced T1-weighted axial MR images with a slice thickness of 2 mm, multiple slices of which covered the entire brain, were obtained by using a Magnetom Impact Expert 1.0-T unit (Siemens); thereafter, a Magnetom Symphony 1.5-T unit (Siemens) was used.

After SRS, patients were usually managed by their referring physicians; clinical and neuroimaging examinations at approximately 2- to 3-month intervals were recommended. However, for 761 (29.8%) of the 2553 patients, neuroimaging follow-up could not be performed because of early post-SRS death or remarkable deterioration of general condition. Among the 2553 patients, follow-up information was obtained during periodic visits to our outpatient clinic (approximately 60%), from clinical and/ or neuroimaging data that were mailed to us (about 25%),

or by phone call from the first author (M.Y.) to patients or their relatives (15%). For deceased patients, information about the day of death, cause of death, and detailed information on patient condition changes was obtained by telephone calls to relatives.

Study Design and Case Matching

Karlsson et al.[13] recently conducted a study of 1921 brain metastasis patients who underwent SRS. They reported that although patients with a single metastatic brain lesion survived longer than those with multiple brain metastases, median survival times did not significantly differ among patients with 2, 3–4, 5–8, or more than 8 metastatic tumors. Also, using our database and including the present cohort (of the 2553 patients, 2232 had 15 tumors or fewer), we used the Kaplan-Meier method[12] to compare 14 pairs of groups based on number of tumors (1 tumor vs 2 tumors, 2 vs 3, 3 vs 4, and so on through 14 vs 15). As shown in Table 1, among the 14 pairs, median survival times differed significantly only for patients with 1 versus 2 tumors (p < 0.001); no significant differences were detected for the other 13 pairs of groups based on number of tumors (Bonferroni threshold 0.05/14 = 0.0036). Thus, we excluded 739 (28.9%) patients with a single metastatic brain lesion and studied the remaining 1814 patients with multiple metastatic brain tumors. These 1814 patients were divided into 2 groups; those with 2–9 tumors (Group A, 1254 patients) and those with 10 or more tumors (Group B, 560 patients).

Because there was bias and a large discrepancy in the number of patients in groups A and B, a case-matched study was conducted by one of the authors (Y.S.), who did not participate in other aspects of this study and was blinded as to the final outcomes. Patient selection was performed by using the propensity score matching method with a Greedy 5-To-1 Digit-Matching algorithm[18] for clinical factors (i.e.,

age, sex, primary tumor status, extracerebral metastases, KPS score, neurological symptoms, prior procedures [surgery and WBRT], volume of the largest tumor, and peripheral doses).[4,21] After all the propensity score matches had been performed, we compared baseline covariates between the 2 groups. Ultimately, 720 patients were selected (360 with 2–9 tumors [Group A] and 360 with 10 or more tumors [Group B]) (Table 2).[33,34] The p values after matching exceeded 0.05 for all clinical factors.

Clinical Outcomes

The primary end point was overall survival, and the secondary end points were neurological death, neurological deterioration, local recurrence of the treated tumor, repeat SRS for new lesions, and SRS-induced major complications. For each end point, failures were regarded as events, and any others were regarded as censored. Because the criteria for each end point have been described,[32,33] they are not repeated herein.

Statistical Analyses

All data were analyzed according to the intention-to-treat principle. For the baseline variables, summary statistics were constructed by using frequencies and proportions for categorical data and using means and standard deviations for continuous variables. We compared patient characteristics by using the Fisher exact test for categorical outcomes and t-tests for continuous variables, as appropriate. The standard Kaplan-Meier method was used for overall and neurological death–free survival calculations.[12] Also, to determine pre-SRS clinical factors favoring longer survival time, we performed univariable analysis by using the Cox proportional hazard model.

For time-to-event outcomes, we estimated the cumulative incidence for local recurrence, repeat SRS, neuro-

TABLE 1: Median survival time differences between patient groups based on number of tumors*

No. of Tumors	No. of Patients	Median Survival Time (95% CI), Months	HR (95% CI)	Log–Rank p Value†
1	739	10.6 (9.4–11.8)		
2	390	7.4 (6.7–8.4)	0.730 (0.641–0.831)	<0.001 (vs 1)
3	235	8.0 (6.4–9.2)	1.046 (0.883–1.236)	0.60 (vs 2)
4	189	7.1 (5.9–8.5)	0.994 (0.815–1.216)	0.96 (vs 3)
5	118	6.2 (5.1–7.6)	0.953 (0.751–1.213)	0.69 (vs 4)
6	115	7.0 (4.8–9.1)	1.030 (0.789–1.345)	0.83 (vs 5)
7	69	8.1 (5.0–10.6)	1.042 (0.759–1.420)	0.79 (vs 6)
8	80	5.5 (3.2–6.5)	0.656 (0.468–0.916)	0.01 (vs 7)
9	57	5.1 (3.7–7.0)	0.888 (0.625–1.253)	0.50 (vs 8)
10	69	7.0 (4.3–9.3)	1.186 (0.824–1.700)	0.35 (vs 9)
11	46	6.3 (3.7–9.1)	0.980 (0.665–1.432)	0.92 (vs 10)
12	32	7.1 (3.5–10.7)	1.063 (0.676–1.694)	0.79 (vs 11)
13	35	6.1 (3.8–8.9)	0.971 (0.591–1.570)	0.96 (vs 12)
14	38	5.7 (2.6–10.0)	0.936 (0.580–1.504)	0.78 (vs 13)
15	20	8.5 (3.8–11.0)	1.038 (0.578–1.810)	0.90 (vs 14)

* Data exclude 4 patients who were lost to follow-up.
† Parentheses indicate number of tumors in comparison group.

TABLE 2: Summary of clinical characteristics of 720 patients with brain metastases*

Characteristic	Total	No. of Tumors 2–9 (Group A)	No. of Tumors ≥10 (Group B)	p Value†
no. of patients	720	360	360	
no. lost to follow-up	3	1 (0.3%)	2 (0.6%)	1.00
no. of tumors				
mean	11	4	17	
median	9, 10	4	14	
range	2–69	2–9	10–69	
age (yrs)				
mean	63	63	63	0.98
range	25–96	26–96	25–91	
sex: female	319 (44.3%)	154 (42.8%)	165 (45.8%)	0.45
primary cancer sites				
lung	498 (69.2%)	251 (69.7%)	247 (68.6%)	0.81‡
breast	101 (14.0%)	49 (13.6%)	52 (14.4%)	
alimentary tract	61 (8.5%)	36 (10.0%)	25 (6.9%)	
kidney	19 (2.6%)	7 (1.9%)	12 (3.3%)	
others	41 (5.7%)	17 (4.7%)	24 (6.7%)	
primary cancer status: controlled	195 (27.1%)	104 (28.9%)	91 (25.3%)	0.31
extracerebral METs: no.	342 (47.5%)	169 (46.9%)	173 (48.1%)	0.82
KPS score ≥80%	542 (75.3%)	269 (74.7%)	273 (75.8%)	0.80
modified-RPA class				
I+IIa	76 (10.6%)	42 (11.7%)	34 (9.4%)	
IIb	220 (30.6%)	106 (29.4%)	114 (31.7%)	0.35§
IIc+III	424 (58.9%)	212 (58.9%)	212 (58.9%)	0.68¶
neurological Sx: no	353 (49.0%)	176 (48.9%)	177 (49.2%)	1.00
prior surgery: yes	103 (14.3%)	54 (15.0%)	49 (13.6%)	0.67
prior WBRT: yes	36 (5.0%)	19 (5.3%)	17 (4.7%)	0.86
tumor volume (cm³)				
cumulative				
mean	10.88	11.45	10.31	0.26
range	0.08–115.3	0.08–115.3	0.15–81.4	
largest tumor				
mean	6.14	6.51	5.77	0.24
range	0.03–94.2	0.04–94.2	0.03–65.0	
peripheral dose (Gy)				
mean	20.62	20.51	20.72	0.35
range	10.00–25.00	10.00–25.00	12.00–25.00	

* KPS = Karnofsky Performance Status; METs = metastases; Sx = symptoms.
† The Student t-test was used for continuous variables and the Fisher exact test for pairs of categorical variables.
‡ Lung vs not lung.
§ Modified RPA Class I+IIa vs IIb.
¶ Modified RPA Class IIb vs IIc+III.

logical deterioration, and major complications by using a competing risk analysis because death is a competing risk for loss to follow-up (i.e., patients who die can no longer become lost to follow-up).[9,12,22] Also, to identify baseline and clinical variables associated with the 4 above-mentioned outcomes, we performed competing risk analyses with the Fine-Gray generalization of the proportional hazards model accounting for death as a competing

risk.[5,7] For modeling cumulative incidence, the Fine-Gray generalization uses the subdistribution hazard, thereby quantifying the overall benefit or harm of an exposure.[2]

All comparisons were planned, and the tests were 2-sided. A p value of less than 0.05 was considered to be statistically significant. All statistical analyses were performed by one of the authors (Y.S.) who used SAS software, version 9.3 (SAS Institute), and the R statistical

program, version 3.0.0. Before statistical analyses, inaccurate records in the database were corrected (by Y.H.). These 2 authors were not involved in either SRS treatment or patient follow-up evaluations.

Results

Four patients were lost to follow-up and excluded from analysis, leaving a cohort of 2549 patients. Among these 2549 patients, the overall post-SRS median survival time was 7.4 (95% CI 7.1–7.9) months. In the subset of 720 patients (excluding 3 patients lost to follow-up [1 in Group A and 2 in Group B]), the median post-SRS follow-up time among censored observations (39 patients) was 16.7 (range 2.1–110.2) months, and 678 (94.2%) patients died. The post-SRS median survival time was 6.4 (95% CI 5.7–7.0) months. Actuarial survival rates after SRS were 51.9%, 27.7%, 10.5%, 4.3%, and 1.6% at 6, 12, 24, 36, and 60 months, respectively. For 40 patients who died, the cause of death could not be determined; but for the remaining 638, the cause of death was confirmed to be non-brain diseases for 576 (90.3%) and brain diseases for 62 (9.7%). Among the subset of 720 patients, salvage surgery was required for 4 patients and WBRT for 29 patients. There were no significant differences between the 2 groups in the incidences of salvage surgery (0.6% vs 0.6%, p = 1.00) and WBRT (3.1% vs 5.0%, p = 0.19) (Table 3).

Comparisons Between Groups A and B

The post-SRS median survival time was slightly longer for patients in Group A (6.8 months) than for those in Group B (6.0 months). However, the median survival time difference, 0.8 months, did not reach statistical significance, as shown in the graph on the left side of Fig. 1 (hazard ratio [HR] 1.133, 95% CI 0.975–1.320, p = 0.10). Incidence rates for death caused by brain disease progression were very similar: 10.0% for Group A and 9.4% for Group B (p = 0.89) (Table 3). Furthermore, neurological death–free survival intervals did not differ significantly between the 2 groups (HR 1.059, 95% CI 0.680–1.649, p = 0.80) (Fig. 1 right).

Post-SRS follow-up MR images were available for 485 (67.4%) patients: 249 (69.2%) in Group A and 236 (65.6%) in Group B (p = 0.34). The median survival time for patients in whom follow-up MRI examinations were not available was 2.3 (95% CI 1.8–2.6) months. Therefore, most patients in this group died or deteriorated remarkably because of extracerebral disease progression before post-SRS MRI examinations could be performed. Among these 485 patients, the incidence of local recurrence was significantly lower for those in Group B than in Group A (3.0% vs 8.4%, p = 0.01) (Table 3). Also, the cumulative incidence of local recurrence differed significantly between the 2 groups (HR 0.425, 95% CI 0.181–0.990, p = 0.04) (Fig. 2A). Our criteria for detecting local recurrence by using MRI and/or methionine positron emission tomography are detailed elsewhere.[31,32]

As shown in Table 3, among the 720 patients, the incidence of repeat SRS for new lesions was significantly lower among patients in Group B than in Group A (23.7% vs 32.3%, p = 0.01). Also, there was a significant difference between the 2 groups in the cumulative incidence of repeat SRS for new lesions (HR 0.732, 95% CI 0.554–0.970, p = 0.03) (Fig. 2B). There were no significant differences between the 2 groups in the incidence of neurological deterioration or SRS-related complications. Also, there were no significant differences between the 2 groups in the cumulative incidence of neurological deterioration (HR 0.994, 95% CI 0.607–1.469, p = 0.80) (Fig. 2C) or SRS-related complications (HR 0.541, 95% CI 0.138–2.112, p = 0.38) (Fig. 2D).

Factors Affecting Longer Survival for Patients With 10 or More Metastatic Brain Tumors

As shown in Table 4, univariable analysis demonstrated that among various pre-SRS clinical factors, significant predictors of a longer survival period for the 360 patients with 10 or more metastatic brain tumors were female sex, younger age, controlled primary cancer, no extracerebral metastases, better KPS score, better modified-RPA class, smaller tumor volume, and higher peripheral dose. Among these 8 factors, hazard ratios were higher for patients with a KPS score of 80% or higher versus

TABLE 3: Crude incidence of outcomes after SRS*

Outcome	Total	2–9 Tumors (Group A)	≥10 Tumors (Group B)	p Value
no. of patients	720	360	360	
neurological death†	62 (9.7)	32 (10.0)	30 (9.4)	0.89
salvage WBRT	29 (4.0)	11 (3.1)	18 (5.0)	0.19
salvage surgery	4 (0.6)	2 (0.6)	2 (0.6)	1.00
local recurrence‡	28 (5.8)	21 (8.4)	7 (3.0)	0.01
repeat SRS	201 (27.9)	116 (32.3)	85 (23.6)	0.01
neurological deterioration	81 (11.3)	45 (12.5)	36 (10.0)	0.35
SRS-related complications	12 (1.7)	9 (2.5)	3 (0.8)	0.14

* Values represent numbers of cases (%).
† Data are for 638 patients for whom cause of death could be determined (319 in Group A and 319 in Group B).
‡ Data are for 485 patients (249 in Group A and 236 in Group B); 235 patients were excluded because neuroimaging results were not available.

Group	MST (95% CI)
——— A (2-9)	6.8 (5.8-7.8) months
·········· B (≥10)	6.0 (5.0-7.0) months

HR: 1.133 (95% CI; 0.975-1.320), p = 0.10

	Actuarial incidences (%)	
Post-SRS (mos)	Group A	Group B
12	28.7	26.7
24	11.3	9.0
36	5.0	3.3

	Actuarial incidences (%)	
Post-SRS (mos)	Group A	Group B
12	88.7	89.1
24	76.6	82.0
36	71.5	61.7

Group	
——— A (2-9)	HR: 1.059 (95% CI; 0.680-1.649)
·········· B (≥10)	p = 0.80

No. at risk

A	359	194	100	59	37	23	15
B	358	175	95	46	28	14	9

No. at risk

A	359	189	96	56	34	21	15
B	358	174	96	46	28	13	9

FIG. 1. Probabilities of overall survival (left) and neurological death–free survival (right) according to number of tumors (2–9 [Group A] and 10 or more [Group B]), estimated by using the Kaplan-Meier method.[12] Three cases lost to follow-up were excluded. MST = median survival time.

70% or lower, primary cancer controlled versus not controlled, no extracerebral metastases versus extracerebral metastases, and modified-RPA Class I+IIa versus IIb and Class IIb versus IIc+III. Also, as shown in Table 4, hazard ratios and 95% confidence intervals for these 4 clinical factors were nearly the same for patients in groups A and B. All of the above-mentioned results differed minimally between the 2 groups.

Discussion

In the study reported here, the post-SRS median survival time difference between the 2 groups, 0.8 months, was not statistically significant. Furthermore, approximately 90% of patients with brain metastases died of causes other than brain disease progression, regardless of the number of metastatic tumors. The results for Group B patients were not inferior to those for Group A patients in terms of neurological death, local recurrence, repeat SRS required for new tumors, maintenance of good neurological state, and SRS-related complications. Because approximately 90% of patients died of extracerebral diseases, it is clearly crucial that brain metastasis treatments contribute to maintenance of a good neurological state. We thus consider it to be very important that the herein-reported results of maintenance of a good neurological state for patients with 10 or more tumors were clearly not inferior to results for patients with 2–9 tumors. Cumulative incidence rates of local recurrence and repeat SRS for patients in Group A were rather high compared with those for patients in Group B; these differences reached statistical significance, although the reasons for their significance are unclear. However, considering our large patient numbers and the fact that the upper 95% CIs (0.990 and 0.970) were very close to 1.0, p values (0.04 and 0.03) were relatively high. Therefore, these differences are not considered to be particularly crucial.

Because we have extensively discussed the benefits of

SRS alone versus WBRT with or without SRS for patients with multiple brain metastases in 2 previous articles,[32,35] we will not repeat them here. However, it is noteworthy that previously published studies show tumor numbers to not significantly affect post-SRS overall survival.[3,13,30,32] The central criticism of SRS alone for treatment of multiple brain metastases is the assumption that frequent microscopic tumors will soon require salvage SRS or other treatments. Thus, WBRT has generally been advocated. However, as reported by Aoyama et al., the longest time that WBRT can be expected to prevent new tumors from arising is 6–8 months.[1] We should remember that considerable numbers of patients with brain metastasis can survive more than 1 year, thereby outliving the effects of WBRT. Fortunately, we already live in an era when a metastatic brain lesion of 0.005 cm³ or even slightly smaller can be detected with thin-slice, gadolinium-enhanced MR images.[11] Hanssens et al. recently reported that according to high-resolution MR imaging, SRS alone decreased the incidence of and lengthened the time to distant recurrences.[10] Although data on periods between SRS and the appearance of new lesions were not available in the study reported here, the rate of repeat SRS among Group B patients was not inferior to that among Group A patients. Therefore, the availability of an alternative treatment for multiple brain metastases enables reservation of WBRT for subsequent treatment attempts (i.e., for meningeal dissemination or miliary metastases treatable only with WBRT).

How Many Brain Metastases Make a Patient Ineligible for SRS?

Current evidence-based guidelines have supported the use of SRS for patients with 1–4 metastatic brain tumors.[17] However, such guidelines frequently lag behind contemporary clinical practice because at least several years are required for completion of rigorous prospective clinical trials. Particularly with use of SRS with a Gamma Knife, when targeting multiple tumors, each addition-

308

FIG. 2. Cumulative incidence of local recurrence (A), repeat SRS (Re-SRS) for new lesions (B), neurological deterioration (C), and major complications (D) according to number of tumors (2–9 [Group A] and 10 or more [Group B]), estimated by using competing risk analysis. Three cases lost to follow-up were excluded. The estimated cumulative incidence of local recurrence was based on 485 (249 in Group A and 236 in Group B) patients (235 patients were excluded because neuroimaging results were not available).

al tumor adds approximately 10 minutes to the treatment time if the tumors are relatively small and a newly loaded unit is used. Therefore, for the past 1.5 decades, challenges have been encountered when using SRS for patients with 5 or more, or even 10 or more, metastatic brain tumors.[3,8,13,15,20,23,24,26,28–30,32] For our cohort of 560 patients with 10 or more tumors, the post-SRS median survival time of 5.6 (95% CI 4.9–6.4) months was slightly longer than the 4 months reported by Rava et al.[20] but similar to the 6 months reported by Grandhi et al.[8]

The North American Gamma Knife Consortium is currently conducting a prospective randomized study entitled "A Randomized Controlled Study Of Neurocognitive Outcomes In Patients With Five Or More Brain Metastases Treated With Radiosurgery Or Whole-Brain Radiotherapy" (http://www.clinicaltrials.gov/, identifier

NCT01731704). The primary aim of that study is to compare the changes in neurocognitive function outcomes between baseline and 6 months among patients who undergo WBRT versus SRS. Patients with more than 4 metastatic brain tumors are eligible for this study. The results are expected to clarify the role of SRS alone versus WBRT.

Is SRS Alone for Multiple Brain Metastases Safe?

In 2002, the first author (M.Y.) and colleagues reported that in a series of 80 patients with 10 or more metastatic brain tumors (median 17, maximum 43) undergoing SRS, the estimated absorbed doses to the whole brain ranged from 2.16 to 8.51 (median 4.71) Gy.[29] It was thus assumed that these doses had not exceeded the threshold level of radiation-induced injury to the whole brain. Kawabe et al. presented evidence, based on 1246 SRS procedures for

22

TABLE 4: Univariable analysis of survival after SRS among 720 matched patients with brain metastases

Factor	No. of Tumors			
	2–9 (Group A)		≥10 (Group B)	
	HR (95% CI)	p Value	HR (95% CI)	p Value
no. of patients	360		360	
sex: M vs F	1.309 (1.054–1.630)	0.01	1.351 (1.090–1.677)	0.006
age				
continuous	1.007 (0.996–1.017)	0.20	1.015 (1.005–1.025)	0.002
>65 vs ≤65 yrs	1.213 (0.976–1.504)	0.08	1.278 (1.032–1.584)	0.02
no. of tumors				
continuous	1.069 (1.018–1.121)	0.007	1.009 (0.995–1.022)	0.22
≤13 vs ≥14			1.141 (0.920–1.417)	0.23
primary cancer: lung vs not lung	1.024 (0.808–1.289)	0.84	1.125 (0.890–1.413)	0.32
extracerebral METs				
controlled vs not controlled	2.726 (2.112–3.550)	<0.001	2.402 (1.856–3.108)	<0.001
present vs absent	1.443 (1.163–1.791)	<0.001	1.347 (1.088–1.670)	0.006
KPS score: ≥80% vs ≤70%	2.140 (1.666–1.725)	<0.001	3.206 (2.467–4.168)	<0.001
modified-RPA class				
I+IIa vs IIb	1.894 (1.298–2.826)	<0.001	1.447 (0.975–2.211)	0.07
IIb vs IIc+III	2.211 (1.728–2.849)	<0.001	2.451 (1.926–3.136)	<0.001
neurological Sx: yes vs no	1.412 (1.139–1.750)	0.002	1.201 (0.970–1.487)	0.09
prior surgery: yes vs no	0.921 (0.671–1.237)	0.59	0.795 (0.579–1.092)	0.15
prior WBRT: yes vs no	0.888 (0.540–1.371)	0.61	1.061 (0.631–1.783)	0.82
tumor volume				
cumulative	1.016 (1.008–1.023)	<0.001	1.023 (1.014–1.032)	<0.001
largest tumor	1.028 (1.014–1.041)	<0.001	1.032 (1.018–1.045)	<0.001
peripheral dose	0.954 (0.921–0.987)	0.007	0.938 (0.901–0.978)	0.003

900 patients with 5 or more metastatic brain tumors, that total absorbed energy for the whole skull of 15 Joules is clearly safe but that total absorbed energy exceeding 20 Joules carries an unacceptably high risk of causing radiation-induced brain injury; the zone between lower and higher risk may thus exist somewhere between 15 and 20 Joules (Kawabe T, Yamamoto M, Barfod BE, Urakawa Y: Gamma knife radiosurgery for multiple brain metastases: what is a safe integral dose for the whole skull? Paper presented at the 10th Congress of International Stereotactic Radiosurgery Society; Paris, France; May 9, 2011). Furthermore, we also recently reported that among 167 brain metastasis patients who survived more than 3 years after SRS, the number of tumors did not affect the incidence of SRS-induced complications (HR 1.066, 95% CI 0.968–1.131, p = 0.1567).[31] Our herein-reported results show no apparent increased risk for complications with SRS for patients with 5 or more metastatic brain tumors compared with 4 or more metastatic brain tumors. Post-SRS MR imaging confirmed the absence of leukoencephalopathy in patients who had undergone SRS alone. Also, in the study reported here, the cumulative incidence of SRS-induced complications among Group B patients was very similar to that among Group A patients. However, only patients with Radiation Therapy Oncology Group neurotoxicity Grade II or worse were counted in this study.[19] Usually, physicians who manage individual cases do not report minor problems like neurotoxicity Grade 0 or 1 to us. Therefore, the weakness of this study is that all patients who experienced minor complications were not surveyed.

How Should Good Candidates for SRS Alone Be Selected From Among Patients With 10 or More Brain Metastases?

Grandhi et al.[8] very recently reported that both univariable and multivariable analyses demonstrated that significant predictors of longer survival were tumor numbers of 13 or fewer versus 14 or more, melanoma versus other primary tumor types, better systemic disease status, and higher RPA class. Our database included only 2 melanoma patients. Thus, we could not test validity for melanoma versus other primary tumor types. In our study, we did not find the number of tumors, either as continuous or categorical variables (13 or fewer vs 14 or more), to be a significant predictor of survival duration (Table 4). Rather, our data indicate the following to favor a longer survival period: controlled primary cancer, no extracerebral metastases, better KPS scores, and higher RPA class. These factors were regarded as the 4 major prognostic factors for selecting good candidates.

Study Weaknesses

The major weakness of this study might be that be-

cause our cohort included all treated patients, clinical factors are obviously heterogeneous. Greater patient group homogeneity makes a study more scientific. However, heterogeneity actually reflects clinical settings rather closely as we physicians often deal with clinical factors that are not homogeneous. Particularly, our database included some patients whose brain metastases were not newly diagnosed. However, proportions of such patients in the 2 groups were very small and did not differ significantly (Table 2). Thus, this heterogeneity had only a minimal effect on our results, as we have reported elsewhere.[33]

Treatment selection is considered to be largely influenced by the characteristics of patients receiving a particular therapeutic regimen. This issue is important when estimating the effect of treatments or exposures on outcomes by using observational data. One approach for reducing or eliminating the effect of treatment selection bias and confounding effects is to use propensity score matching, which enables one to design and analyze an observational (nonrandomized) study that mimics some of the characteristics of a randomized controlled trial.[4] Original tumor phenotypes are now known to affect patient survival. Because these data were lacking for most patients who underwent SRS in the earlier years of our study period, we could not include them as a clinical factor for case matching.

Conclusions

Post-SRS treatment results (i.e., median survival time; neurological death–free survival time; and cumulative incidence of local recurrence, repeat SRS for new lesions, neurological deterioration, and SRS-related complications were not inferior among Group B patients when compared with those among Group A patients. We conclude that carefully selected patients with 10 or more metastatic brain tumors are not unfavorable candidates for SRS alone. However, a randomized controlled trial is necessary, in the near future, to clarify the most appropriate role for SRS alone in patients with 10 or more metastatic brain tumors.

Disclosure

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author contributions to the study and manuscript preparation include the following. Conception and design: Yamamoto. Acquisition of data: Yamamoto, Kawabe, Watanabe. Analysis and interpretation of data: Yamamoto, Kawabe, Nariai. Critically revising the article: Yamamoto. Reviewed submitted version of manuscript: Yamamoto, Kawabe, Sato, Higuchi, Nariai, Kasuya. Approved the final version of the manuscript on behalf of all authors: Yamamoto. Statistical analysis: Sato, Higuchi. Study supervision: Yamamoto, Kasuya.

References

1. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hata-no K, et al: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. **JAMA 295:**2483–2491, 2006
2. Bakoyannis G, Touloumi G: Practical methods for competing risks data: a review. **Stat Methods Med Res 21:**257–272, 2012
3. Chang WS, Kim HY, Chang JW, Park YG, Chang JH: Analysis of radiosurgical results in patients with brain metastases according to the number of brain lesions: is stereotactic radiosurgery effective for multiple brain metastases? Clinical article. **J Neurosurg 113 Suppl:**73–78, 2010
4. D'Agostino RB Jr: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. **Stat Med 17:**2265–2281, 1998
5. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. **J Am Stat Assoc 94:**496–509, 1999
6. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. **Int J Radiat Oncol Biol Phys 37:**745–751, 1997
7. Gooley TA, Leisenring W, Crowley J, Storer BE: Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. **Stat Med 18:**695–706, 1999
8. Grandhi R, Kondziolka D, Panczykowski D, Monaco EA III, Kano H, Niranjan A, et al: Stereotactic radiosurgery using the Leksell Gamma Knife Perfexion unit in the management of patients with 10 or more brain metastases. Clinical article. **J Neurosurg 117:**237–245, 2012
9. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. **Ann Stat 16:**1141–1154, 1988
10. Hanssens P, Karlsson B, Yeo TT, Chou N, Beute G: Detection of brain micrometastases by high-resolution stereotactic magnetic resonance imaging and its impact on the timing of and risk for distant recurrences. Clinical article. **J Neurosurg 115:**499–504, 2011
11. Hayashi M, Yamamoto M, Nishimura C, Satoh H: Do recent advances in MR technologies contribute to better gamma knife radiosurgery treatment results for brain metastases? **Neuroradiol J 20:**481–490, 2007
12. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. **J Am Stat Assoc 53:**457–481, 1958
13. Karlsson B, Hanssens P, Wolff R, Söderman M, Lindquist C, Beute G: Thirty years' experience with Gamma Knife surgery for metastases to the brain. Clinical article. **J Neurosurg 111:**449–457, 2009
14. Karnofsky DA, Buechenal JH: The clinical evaluation of chemotherapeutic agents in cancer, in MacLeod CM (ed): **Evaluation of Chemotherapeutic Agent.** New York: Columbia University Press, 1949, pp 191–205
15. Kim CH, Im YS, Nam DH, Park K, Kim JH, Lee JI: Gamma knife radiosurgery for ten or more brain metastases. **J Korean Neurosurg Soc 44:**358–363, 2008
16. Knisely JPS, Yamamoto M, Gross CP, Castrucci WA, Jokura H, Chiang VLS: Radiosurgery alone for 5 or more brain metastases: expert opinion survey. Clinical article. **J Neurosurg 113 Suppl:**84–89, 2010
17. Linskey ME, Andrews DW, Asher AL, Burri SH, Kondziolka D, Robinson PD, et al: The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. **J Neurooncol 96:**45–68, 2010
18. Parsons LS: Reducing bias in a propensity score matched-pair sample using greedy matching techniques. **SAS.** (http://www2.sas.com/proceedings/sugi26/p214-26.pdf) [Accessed August 11, 2014]

19. Radiation Therapy Oncology Group: **Cooperative Group Common Toxicity Criteria.** (http://www.rtog.org/Research Associates/AdverseEventReporting/CooperativeGroup CommonToxicityCriteria.aspx) [Accessed August 13, 2014]

20. Rava P, Leonard K, Sioshansi S, Curran B, Wazer DE, Cosgrove GR, et al: Survival among patients with 10 or more brain metastases treated with stereotactic radiosurgery. Clinical article. **J Neurosurg 119**:457–462, 2013

21. Rosenbaum PR, Rubin DB: The central role of the propensity score in observational studies for causal effects. **Biometrika 70**:41–55, 1983

22. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD: A note on competing risks in survival data analysis. **Br J Cancer 91**:1229–1235, 2004

23. Serizawa T, Hirai T, Nagano O, Higuchi Y, Matsuda S, Ono J, et al: Gamma knife surgery for 1-10 brain metastases without prophylactic whole-brain radiation therapy: analysis of cases meeting the Japanese prospective multi-institute study (JLGK0901) inclusion criteria. **J Neurooncol 98**:163–167, 2010

24. Serizawa T, Yamamoto M, Sato Y, Higuchi Y, Nagano O, Kawabe T, et al: Gamma Knife surgery as sole treatment for multiple brain metastases: 2-center retrospective review of 1508 cases meeting the inclusion criteria of the JLGK0901 multi-institutional prospective study. Clinical article. **J Neurosurg 113 Suppl**:48–52, 2010

25. Sturm V, Kober B, Höver KH, Schlegel W, Boesecke R, Pastyr O, et al: Stereotactic percutaneous single dose irradiation of brain metastases with a linear accelerator. **Int J Radiat Oncol Biol Phys 13**:279–282, 1987

26. Suzuki S, Omagari J, Nishio S, Nishiye E, Fukui M: Gamma knife radiosurgery for simultaneous multiple metastatic brain tumors. **J Neurosurg 93 Suppl 3**:30–31, 2000

27. Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, et al: Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. **Pract Radiat Oncol 2**:210–225, 2012

28. Yamamoto M, Ide M, Jimbo M, Aiba M, Ito M, Hirai H, et al: Gamma knife radiosurgery with numerous target points for intracranially disseminated metastases: early experience in three patients and experimental analysis of whole brain irradiation doses, in Kondziolka D (ed): **Radiosurgery 1997.** Basel: Karger, 1998, Vol 2, pp 94–109

29. Yamamoto M, Ide M, Nishio Si, Urakawa Y: Gamma Knife radiosurgery for numerous brain metastases: is this a safe treatment? **Int J Radiat Oncol Biol Phys 53**:1279–1283, 2002

30. Yamamoto M, Kawabe T, Barfod BE: How many metastases can be treated with radiosurgery? **Prog Neurol Surg 25**:261–272, 2012

31. Yamamoto M, Kawabe T, Higuchi Y, Sato Y, Nariai T, Barfod BE, et al: Delayed complications in patients surviving at least 3 years after stereotactic radiosurgery for brain metastases. **Int J Radiat Oncol Biol Phys 85**:53–60, 2013

32. Yamamoto M, Kawabe T, Sato Y, Higuchi Y, Nariai T, Barfod BE, et al: A case-matched study of stereotactic radiosurgery for patients with multiple brain metastases: comparing treatment results for 1–4 vs ≥ 5 tumors. Clinical article. **J Neurosurg 118**:1258–1268, 2013

33. Yamamoto M, Sato Y, Serizawa T, Kawabe T, Higuchi Y, Nagano O, et al: Subclassification of recursive partitioning analysis Class II patients with brain metastases treated radiosurgically. **Int J Radiat Oncol Biol Phys 83**:1399–1405, 2012

34. Yamamoto M, Serizawa T, Sato Y, Kawabe T, Higuchi Y, Nagano O, et al: Validity of two recently-proposed prognostic grading indices for lung, gastro-intestinal, breast and renal cell cancer patients with radiosurgically-treated brain metastases. **J Neurooncol 111**:327–335, 2013

35. Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, et al: Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective study. **Lancet Oncol 15**:387–395, 2014

Intractable yawning associated with mature teratoma of the supramedial cerebellum

Case report

HIROAKI SAURA, M.D.,[1] TAKAAKI BEPPU, M.D.,[1] HIDEKI MATSUURA, M.D.,[1]
SHIGEKI ASAHI, M.D.,[2] NORIYUKI UESUGI, M.D.,[3] MAKOTO SASAKI, M.D.,[4]
AND KUNIAKI OGASAWARA, M.D.[1]

Departments of [1]Neurosurgery and [3]Diagnostic Pathology and [4]Division of Ultrahigh Field MRI, Institute for Biomedical Sciences Iwate Medical University, Morioka; and [2]Kohnodai Hospital National Center of Global Health and Medicine, Ichikawa, Japan

Yawning occurs in various conditions such as hypoxia, epilepsy, and sleep disorders including sleep apnea. Intractable yawning associated with a brain tumor has been rarely reported. A 19-year-old woman presented with intractable yawning. Magnetic resonance imaging showed a tumor in the supramedial cerebellum that compressed the dorsal side of the midbrain and upper pons. After subtotal removal of the tumor, the yawning completely disappeared. Postoperative MRI showed resolution of compression of the brainstem. The tumor was histologically diagnosed as a mature teratoma. The present case suggested that the intractable yawning resulted from the tumor compressing the dorsal side of the junction between the midbrain and pons.
(http://thejns.org/doi/abs/10.3171/2014.4.JNS132243)

KEY WORDS   •   yawning   •   paraventricular nucleus   •   parabrachial nucleus   • oncology

YAWNING occurs in various conditions such as hypoxia, epilepsy, and sleep disorders, including sleep apnea. Neural networks among the pons, hypothalamus, limbic system, and autonomic nervous system may be associated with yawning.[3,6,8,9] However, intractable yawning associated with a brain tumor has rarely been reported.[1]

We report a rare case involving a patient who had a mature teratoma in the supramedial cerebellum and suffered from intractable yawning. After subtotal removal of the tumor, the yawning completely disappeared.

Case Report

History and Examination. A 19-year-old woman with

recurrent yawning visited a local hospital, and an intracranial mass was detected on MRI. The patient visited our institution 4 weeks after symptom onset. The yawning occurred 20 times per minute and continued for approximately 60–90 minutes. Such yawning attacks occurred 2 or 3 times per week. Neurological examination demonstrated no abnormal findings. Magnetic resonance imaging depicted a high-intensity mass in the supramedial cerebellum on T1- and T2-weighted images (Fig. 1). The tumor compressed the dorsal midbrain and upper pons.

Blood gas analysis findings, including partial oxygen pressure, were within normal limits during yawning. Blood counts and biochemical data were also within normal limits. Although the patient's score was 20/24 on the Epworth Sleepiness Scale for detection of sleep disorders (normal score < 11), polysomnography showed no abnormality. Electroencephalography also demonstrated no abnormality. After improving her daily living environment according to our advice, the patient's Epworth Sleepi-

FIG. 1. Axial T1-weighted (A), axial T2-weighted (B), and sagittal Gd-enhanced T1-weighted MR images (C) obtained when the patient presented to our institution, showing a high-intensity mass in the supramedial cerebellum that compresses the dorsal midbrain and the upper pons.

ness Scale score declined to 9/24. However, the yawning continued for 2 years after the decrease in the Epworth Sleepiness Scale score, and then diplopia developed. Neurological examination demonstrated a right trochlear nerve palsy. Magnetic resonance imaging showed no change in the tumor.

Operation and Postoperative Course. The patient underwent removal of the tumor through an occipital transtentorial approach performed under general anesthesia. The tumor was hard and contained yellowish fat tissue and calcified components. During surgery, we found that the tumor adhered to the dorsal side of the midbrain and upper pons and involved the right trochlear nerve and the right superior cerebellar artery. Therefore, the tumor except the part adhering to the dorsal midbrain was removed. The surgical specimen was histologically diagnosed as a mature teratoma composed of fat, muscle, and nerve cells with poor heteromorphism. The yawning completely disappeared immediately after surgery and has not recurred 7 months after surgery. Postoperative MRI showed a residual tumor at the dorsal midbrain and resolution of the brainstem compression (Fig. 2).

Discussion

Based on blood gas analysis, the Epworth Sleepiness Scale score, and findings on polysomnography and electroencephalography, intractable yawning in this patient was likely not caused by hypoxia, epilepsy, or a sleep disorder such as sleep apnea. Furthermore, the yawning disappeared immediately after surgery and did not recur after surgery. These findings suggested that the yawning was associated with a tumor in the supramedial cerebellum that compressed the dorsal midbrain and upper pons.

The parabrachial area is located on the dorsal side of the junction of the midbrain and pons and plays a role in unifying the autonomic nervous system.[4,5,7] In the human brain, the parabrachial area is a horseshoe-shaped band of gray matter composed of the lateral parabrachial nucleus (PBN), the Kölliker-Fuse nucleus, and the medial PBN (Fig. 3 upper). These nuclei receive important afferent fibers from the cardiovascular, respiratory, and gustatory systems and project efferent fibers toward superior

centers.[5] On the other hand, the paraventricular nucleus (PVN), which is located in the medial hypothalamus, is a center of the autonomic nervous system and neuroendocrine system, and it is closely associated with yawning (Fig. 3 lower).[4,6] An experimental study in rats demonstrated the occurrence of yawning upon electrical or chemical stimulation of the PVN.[8] Furthermore, the PVN has reciprocal connections with brainstem autonomic centers including the PBN.[2] In particular, the PVN transmits signals mainly from the lateral PBN.[7] In the present case, any extraordinary stimulation from the lateral PBN in the brainstem to the PVN in the hypothalamus may have led to the development of pathological yawning.

In this case, MRI showed that the tumor preoperatively compressed the dorsal side of the midbrain and up-


FIG. 2. Postoperative sagittal Gd-enhanced T1-weighted MR image revealing a residual tumor at the dorsal midbrain and resolution of compression of the brainstem.

388

Intractable yawning associated with mature teratoma

Fig. 3. **Upper:** The parabrachial area is composed of the lateral PBN (a), the Kölliker-Fuse nucleus (b), and the medial PBN (c). **Lower:** The PVN is localized in the medial hypothalamus.

per pons, and this condition was resolved after surgery. These findings suggested that the intractable yawning might have resulted from the tumor compressing the PBN located on the dorsal side of the junction of the midbrain and pons.

References

1. Arai K, Kita K, Komiyama A, Hirayama K, Saeki N, Nagao K: [Progressive dysautonomia in hemangioblastoma in the region of the fourth ventricle.] **No To Shinkei 38:**195–200, 1986 (Jpn)
2. Blair ML, Piekut D, Want A, Olschowka JA: Role of the hypothalamic paraventricular nucleus in cardiovascular regulation. **Clin Exp Pharmacol Physiol 23:**161–165, 1996
3. Cronin TG Jr: Yawning: an early manifestation of vasovagal reflex. **AJR Am J Roentgenol 150:**209, 1988 (Letter)
4. Honda K, Higuchi T: Role of midbrain parabrachial nucleus in controlling electrical activity of oxytocin and vasopressin secreting neurones in the hypothalamic supraoptic nucleus. **J Reprod Dev 47:**259–265, 2001
5. Kiernan JA: **Barr's The Human Nervous System: An Anatomical Viewpoint, ed 9.** Baltimore: Lippincott Williams & Wilkins, 2009, pp 147–148
6. Kita I, Sato-Suzuki I, Oguri M, Arita H: Yawning responses induced by local hypoxia in the paraventricular nucleus of the rat. **Behav Brain Res 117:**119–126, 2000
7. Naidich TP, Duvernoy HM, Delman BN, Sorensen AG, Kollias SS, Haacke EM: **Duvernoy's Atlas of the Human Brain Stem and Cerebellum: High-Field MRI: Surface Anatomy, Internal Structure, Vascularization and 3D Sectional Anatomy.** New York: Springer, 2009, p 324
8. Sato-Suzuki I, Kita I, Oguri M, Arita H: Stereotyped yawning responses induced by electrical and chemical stimulation of paraventricular nucleus of the rat. **J Neurophysiol 80:**2765–2775, 1998
9. Ueyama T, Senba E: [Limbic system and autonomic nervous system.] **Rinsho Shinkeigaku 50:**1003–1006, 2010 (Jpn)

315

Pineal parenchymal tumor of intermediate differentiation: Treatment outcomes of five cases

TSUBASA WATANABE[1], TAKASHI MIZOWAKI[1], YOSHIKI ARAKAWA[2], YUSUKE IIZUKA[1], KENGO OGURA[1], KATSUYUKI SAKANAKA[1], SUSUMU MIYAMOTO[2] and MASAHIRO HIRAOKA[1]

Departments of [1]Radiation Oncology and Image-Applied Therapy, and [2]Neurosurgery, Kyoto University Graduate School of Medicine, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan

Abstract. Pineal parenchymal tumor of intermediate differentiation (PPTID) is a rare disease, first classified by the World Health Organization in 2000. The number of available studies on the treatment of PPTID is currrently limited and the optimal management for this disease has not yet been determined. We retrospectively evaluated the treatment outcomes for PPTID at our institute and analyzed the roles of radiation therapy and chemotherapy for this disease. The clinical data on five patients diagnosed with PPTID since 2000 were retrospectively reviewed. Patients with cerebrospinal dissemination at diagnosis received biopsy-only surgery, craniospinal and whole-ventricular irradiation and chemotherapy. Patients with locally limited disease at diagnosis received local or whole-ventricular irradiation after surgery. The median relapse-free and overall survival were 72.9 and 94.1 months, respectively. Two of the five patients developed a relapse of cerebrospinal dissemination after treatment and succumbed to the disease. All the patients who received both craniospinal and whole-ventricular irradiation exhibited evidence of cerebral white matter abnormalities in magnetic resonance imaging and developed neurocognitive disorders after treatment. Although PPTID may be aggressive and has cerebrospinal fluid seeding potential, PPTID patients may survive long-term, even after recurrence. Considering the long survival time and the late adverse effects due to intensive treatment, the irradiation field and usage of chemotherapy after surgery require optimization.

Correspondence to: Dr Takashi Mizowaki, Department of Radiation Oncology and Image-Applied Therapy, Kyoto University Graduate School of Medicine, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
E-mail: mizo@kuhp.kyoto-u.ac.jp

Introduction

Pineal parenchymal tumors are rare, accounting for <0.3% of all primary central nervous system tumors (1). Pineal parenchymal tumors are heterogeneous entities, exhibiting considerable morphological variation. According to the WHO classification for tumors of the central nervous system (2007 revision), these tumors are histologically subdivided into pineocytoma (grade I), pineoblastoma (grade IV), papillary tumor of the pineal region (grade II or III) and pineal parenchymal tumor of intermediate differentiation (PPTID) (grade II or III) (2,3). PPTID is a fairly recently defined disease. It was first classified by the WHO in 2000 as a pineal parenchymal tumor with an intermediate prognosis between pineocytoma and pineoblastoma. Determination of the mitotic index and immunohistochemistry are used to pathologically classify PPTIDs as grade II or III (2,3).

The treatment for pineal parenchymal tumors is histology-dependent. Pineocytomas are treated with surgical resection. If complete or subtotal resection is accomplished, the outcome is favorable, even without adjuvant treatment (4,5). By contrast, the treatment of pineoblastomas should consist of surgery as well as adjuvant treatment, including chemotherapy and craniospinal irradiation. Occasionally, even more aggressive treatment, including myeloablative chemotherapy with stem cell rescue, may be required for the treatment of pineoblastomas (6).

Unlike other histological subtypes, the optimal management for PPTIDs remains to be determined, as it was relatively recently characterized and is rather rare. In one series, patients with PPTID who were treated with surgery alone survived free of disease (7). At the other extreme, another study described PPTIDs as tumors with seeding potential and recommended postoperative treatment in a manner similar to that for pineoblastomas (1). To the best of our knowledge, the number of available studies on the treatment of PPTID is limited, particularly regarding radiation therapy and chemotherapy (8-10), whereas there are currently no treatment reports for PPTID cases alone. The aim of this study was to retrospectively evaluate the treatment outcomes of patients with PPTID who received treatment at our institute and analyze the effects of radiation therapy and chemotherapy on this disease.

Materials and methods

Record review. We conducted a retrospective record review for patients who were diagnosed with PPTID and treated with radiation therapy at our institute from 2000 onwards. Clinical data, including Eastern Cooperative Oncology Group performance status and Karnofsky performance status, pathological results, imaging [computed tomography (CT) and magnetic resonance imaging (MRI)], initial treatment, resection status, details of chemotherapy, details of radiation therapy, initial response to treatment, recurrence pattern and late adverse toxicities, were collected.

The extent of surgical resection was assessed according to the surgical and pathological reports and postoperative imaging. The resection status was classified as previously described: 'gross total resection' was defined as no evidence of contrast-enhancing tumor on postoperative images; 'R2-resection' was any surgical tumor resection less than gross total resection; and 'biopsy only' was no surgical tumor resection due to inoperability, with a biopsy performed to determine tumor histology (10). The response to treatment was assessed based on serial measurements of CT or MRI scans.

The criteria for response were as follows: complete response (CR), disappearance of tumor; partial response (PR), >50% decrease in tumor size; progressive disease, >25% increase in tumor size or any appearance of new sites; stable disease, all other situations. Relapse-free and overall survival were calculated from the initiation of radiation therapy to the date of relapse and to the date of death or last follow-up, respectively. The endpoint of the analysis was the date of either the last follow-up or the patient's death.

The appearance or exacerbation of cerebral white matter abnormalities in MRI after treatment, neurocognitive effects, pituitary function and incidence of cerebrovascular disease were investigated as late effects of treatment, according to the grading system of Radiation Therapy Oncology Group (RTOG) common toxicity criteria and Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. The details of the classification according to neurocognitive disorders are as follows: RTOG (neurological/cortical) grade 1, mild somnolence or agitation; grade 2, moderate somnolence or agitation; grade 3, severe somnolence, agitation, confusion, disorientation or hallucinations; and grade 4, coma, seizures and toxic paralysis; and CTCAE (cognitive disturbance) grade 1, mild cognitive disability, not interfering with work/school/life performance, specialized educational services/devices not indicated; grade 2, moderate cognitive disability, interfering with work/school/life performance but capable of independent living, specialized resources indicated on a part-time basis; grade 3, severe cognitive disability, with significant impairment of work/school/life performance; and grade 4, unable to perform activities of daily living, with full-time specialized resources or institutionalization indicated.

Patients. Five patients were diagnosed with PPTID and treated at our institute between 2000 and 2011. Table I summarizes the patients' backgrounds, tumor pathological characteristics and treatment received. Two patients were male and three were female. The median age at diagnosis was 52 years (range, 30-55 years). Two patients had evidence of cerebrospinal dissemination at diagnosis, as assessed by radiological findings or cerebrospinal fluid (CSF) cytology. A cytological examination of the CSF was performed prior to chemotherapy and radiation therapy and craniospinal imaging was performed throughout the therapy. The grade of the disease was determined according to the number of mitoses and immunostaining for neurofilaments (grade 2, <6 mitoses and strongly immunopositive for neurofilaments; grade 3, >6 mitoses or <6 mitoses, but without strong immunostaining for neurofilaments) (2). The five patients were pathologically classified as WHO grade 2 according to pathological criteria (Table I).

Treatment. None of the patients underwent a gross total resection, due to the difficulty of tumor location and invasion toward the thalamus or the surrounding eloquent area. Three of the five patients had an R2-resection and the remaining two patients, who had cerebrospinal dissemination at diagnosis, had biopsy-only surgery (Table I).

All the patients were treated with external beam radiation therapy with a 1.8-Gy fraction dose after surgery. Among the five patients, two received 54 Gy directed at the primary lesion following R2-resection; the two patients with cerebrospinal dissemination at diagnosis received 36 Gy of craniospinal irradiation and 18 Gy of whole-ventricular irradiation after biopsy-only surgery. The remaining patient was initially planned to receive 59.4 Gy of whole-ventricular irradiation with concurrent chemotherapy following R2-resection; however, irradiation was discontinued after administering 34.2 Gy due to severe sepsis after chemotherapy.

Four of the patients received six courses of combination chemotherapy with vincristine (0.6 mg/m^2), nimustine (60 mg/m^2), carboplatin (110 mg/m^2) and interferon β (3x10^6 IU) on day 1 and the same dose of vincristine and interferon β on days 8 and 15 (Table I). The remaining patient was administered radiation therapy alone following R2-resection. The two patients with cerebrospinal dissemination at diagnosis received sequential chemotherapy after radiation therapy and the two patients without dissemination received concurrent chemotherapy with radiation therapy after surgery.

All five patients underwent follow-up MRI or CT every 2 months during the first year after treatment. Further MRI or CT follow-up were performed every 4-6 months after the first year of follow-up.

Results

Outcome. Table II summarizes the treatment results of the five PPTID patients included in the present study. The patients appeared to have long-term survival. The median relapse-free and overall survival were 72.9 and 94.1 months, respectively (mean relapse-free survival, 65.1 months; range, 13.9-108.6 months; and mean overall survival, 79.9 months; range, 13.9-108.6 months). Three of the five patients achieved a CR and two attained a PR as an initial response to treatment (Table II). Although two of the patients developed a recurrence after treatment, they survived long-term after treatment, with overall survival times of 106.1 and 76.8 months (Table II). These results demonstrated that, with optimized surgery, radiation therapy and chemotherapy, PPTID patients have the potential for long-term survival.

Table I. Patients' backgrounds, tumor pathological characteristics and treatment details.

Case no.	Age/gender [PS/KPS] (years)	Tumor size (mm)	Dissemination at time of diagnosis	Pathology WHO grade	NFI	Mitoses (/10 HPF)	Ki-67 (%)	Surgery	Radiation therapy	Chemotherapy
1	46/M [3/70]	38	-	2	Focal	0	1	R2	Local 54 Gy	-
2	55/F [1/90]	37	-	2	+	0	15	R2	WVI 34.2 Gy	Concurrent
3	52/F [1/90]	22	+	2	+	0	10-15	Biopsy	CSI 36 Gy + WVI 18 Gy	Sequential
4	55/F [1/90]	30	+	2	+	0-1	5	Biopsy	CSI 36 Gy + WVI 18 Gy	Sequential
5	30/M [2/80]	25	-	2	+	0-1	1-2	R2	Local 54Gy	Concurrent

PS, Eastern Cooperative Oncology Group performance status; KPS, Karnofsky performance status; M, male; F, female; WHO, World Health Organisation; NFI, neurofilament immunostaining; HPF, high-power fields; R2, R2-resection; WVI, whole-ventricular irradiation; CSI, craniospinal irradiation.

Table II. Treatment outcomes and late adverse events after treatment.

Case no.	Initial response	Alive (recurrence)	Relapse-free survival (months)	Overall survival (months)	Late effects after treatment White matter abnormalities (time after RT)	Neurocognitive disorders (time after RT)	Pituitary function disorders	Cerebrovascular disorders
1	CR	No (yes)	36.0	106.1	-	-	-	-
2	CR	Yes (no)	108.6	108.6	Yes (6 months)	-	-	-
3	PR	Yes (no)	94.1	94.1	Yes (7 months)	Yes (6 years)	GH deficiency Hypothyroidism	-
4	PR	No (yes)	72.9	76.8	Yes (5 months)	Yes (4 years)	GH deficiency	-
5	CR	Yes (no)	13.9	13.9	-	-	-	-

RT, radiotherapy; CR, complete response; PR, partial response; GH, growth hormone.